The Next Generation of Alzheimer’s Treatment: Harnessing Microglia with TREM2 Agonism

Time: 1:30 pm
day: Clinical & Commercial Track Day 2 PM


  • Harnessing neuroprotective microglial states for the next generation of AD treatment
  • Potent small molecule TREM2 agonists that act as molecular glues to stabilize a multimeric signalling complex
  • Genetic and biomarker strategies to aid early development and how a small molecule TREM2 agonist may address unmet needs in AD